Nicholas A. Smith

Array ( [id] => 5514220 [patent_doc_number] => 20090214526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-08-27 [patent_title] => 'Optimized Fc Variants and Methods for Their Generation' [patent_app_type] => utility [patent_app_number] => 11/927488 [patent_app_country] => US [patent_app_date] => 2007-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 84987 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0214/20090214526.pdf [firstpage_image] =>[orig_patent_app_number] => 11927488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4791648 [patent_doc_number] => 20080292621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-11-27 [patent_title] => 'Optimized Fc Variants and Methods for Their Generation' [patent_app_type] => utility [patent_app_number] => 11/927463 [patent_app_country] => US [patent_app_date] => 2007-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 85032 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0292/20080292621.pdf [firstpage_image] =>[orig_patent_app_number] => 11927463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4785009 [patent_doc_number] => 20080138338 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-06-12 [patent_title] => 'POLYPEPTIDE VARIANTS' [patent_app_type] => utility [patent_app_number] => 11/871335 [patent_app_country] => US [patent_app_date] => 2007-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 24307 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 11871335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6367921 [patent_doc_number] => 20100074886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-03-25 [patent_title] => 'CCR2 ANTAGONISTS FOR TREATMENT OF FIBROSIS' [patent_app_type] => utility [patent_app_number] => 12/442404 [patent_app_country] => US [patent_app_date] => 2007-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 14926 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0074/20100074886.pdf [firstpage_image] =>[orig_patent_app_number] => 12442404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4697790 [patent_doc_number] => 20080219974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-09-11 [patent_title] => 'OPTIMIZED ANTIBODIES THAT TARGET HM1.24' [patent_app_type] => utility [patent_app_number] => 11/857310 [patent_app_country] => US [patent_app_date] => 2007-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 42288 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0219/20080219974.pdf [firstpage_image] =>[orig_patent_app_number] => 11857310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4852003 [patent_doc_number] => 20080317745 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-12-25 [patent_title] => 'Methods of diagnosing, treating, or preventing plasma cell disorders' [patent_app_type] => utility [patent_app_number] => 11/898932 [patent_app_country] => US [patent_app_date] => 2007-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 38861 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0317/20080317745.pdf [firstpage_image] =>[orig_patent_app_number] => 11898932 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4771398 [patent_doc_number] => 20080057056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-03-06 [patent_title] => 'Fc Variants with Increased Affinity for FcyRIIC' [patent_app_type] => utility [patent_app_number] => 11/841718 [patent_app_country] => US [patent_app_date] => 2007-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 93 [patent_figures_cnt] => 93 [patent_no_of_words] => 58628 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0057/20080057056.pdf [firstpage_image] =>[orig_patent_app_number] => 11841718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6201941 [patent_doc_number] => 20110064727 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2011-03-17 [patent_title] => 'Immunoglobulin Variants Outside the Fc Region' [patent_app_type] => utility [patent_app_number] => 11/841530 [patent_app_country] => US [patent_app_date] => 2007-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 29741 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A9/0064/20110064727.pdf [firstpage_image] =>[orig_patent_app_number] => 11841530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5515684 [patent_doc_number] => 20090215991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-08-27 [patent_title] => 'Optimized Fc Variants and methods for their generation' [patent_app_type] => utility [patent_app_number] => 11/841755 [patent_app_country] => US [patent_app_date] => 2007-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 92 [patent_no_of_words] => 58639 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0215/20090215991.pdf [firstpage_image] =>[orig_patent_app_number] => 11841755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4753465 [patent_doc_number] => 20080161541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-07-03 [patent_title] => 'Fc Variants with Increased Affinity for FcyRIIc' [patent_app_type] => utility [patent_app_number] => 11/841843 [patent_app_country] => US [patent_app_date] => 2007-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 70 [patent_figures_cnt] => 70 [patent_no_of_words] => 58619 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 11841843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6201941 [patent_doc_number] => 20110064727 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2011-03-17 [patent_title] => 'Immunoglobulin Variants Outside the Fc Region' [patent_app_type] => utility [patent_app_number] => 11/841530 [patent_app_country] => US [patent_app_date] => 2007-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 29741 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A9/0064/20110064727.pdf [firstpage_image] =>[orig_patent_app_number] => 11841530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4734583 [patent_doc_number] => 20080051563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-02-28 [patent_title] => 'Fc Variants with Increased Affinity for FcyRIIc' [patent_app_type] => utility [patent_app_number] => 11/841821 [patent_app_country] => US [patent_app_date] => 2007-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 93 [patent_figures_cnt] => 93 [patent_no_of_words] => 58624 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0051/20080051563.pdf [firstpage_image] =>[orig_patent_app_number] => 11841821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9827930 [patent_doc_number] => 08937158 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-01-20 [patent_title] => 'Fc variants with increased affinity for FcγRIIc' [patent_app_type] => utility [patent_app_number] => 11/841654 [patent_app_country] => US [patent_app_date] => 2007-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 73 [patent_no_of_words] => 58628 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 11841654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9009569 [patent_doc_number] => 08524867 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-09-03 [patent_title] => 'Optimized antibodies that target CD19' [patent_app_type] => utility [patent_app_number] => 12/377251 [patent_app_country] => US [patent_app_date] => 2007-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 37 [patent_no_of_words] => 48122 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12377251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5270991 [patent_doc_number] => 20090074767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-03-19 [patent_title] => 'Isolated human phosphodiesterase proteins, nucleic acid molecules encoding human phosphodiesterase proteins, and uses thereof' [patent_app_type] => utility [patent_app_number] => 11/889561 [patent_app_country] => US [patent_app_date] => 2007-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 101 [patent_figures_cnt] => 101 [patent_no_of_words] => 19581 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0074/20090074767.pdf [firstpage_image] =>[orig_patent_app_number] => 11889561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4886399 [patent_doc_number] => 20080260731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-10-23 [patent_title] => 'OPTIMIZED ANTIBODIES THAT TARGET CD19' [patent_app_type] => utility [patent_app_number] => 11/838824 [patent_app_country] => US [patent_app_date] => 2007-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 48374 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0260/20080260731.pdf [firstpage_image] =>[orig_patent_app_number] => 11838824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4734584 [patent_doc_number] => 20080051564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-02-28 [patent_title] => 'Delivery of pharmaceutical agents via the human insulin receptor' [patent_app_type] => utility [patent_app_number] => 11/893281 [patent_app_country] => US [patent_app_date] => 2007-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10282 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0051/20080051564.pdf [firstpage_image] =>[orig_patent_app_number] => 11893281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9299943 [patent_doc_number] => 08648171 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-02-11 [patent_title] => 'Members of the FC receptor homolog gene family (FcRH1-3,6) related reagents and uses thereof' [patent_app_type] => utility [patent_app_number] => 11/835226 [patent_app_country] => US [patent_app_date] => 2007-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 21954 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 11835226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4898891 [patent_doc_number] => 20080118505 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-05-22 [patent_title] => 'Reagents and treatment methods for autoimmune diseases' [patent_app_type] => utility [patent_app_number] => 11/890743 [patent_app_country] => US [patent_app_date] => 2007-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 15325 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0118/20080118505.pdf [firstpage_image] =>[orig_patent_app_number] => 11890743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4927396 [patent_doc_number] => 20080166759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-07-10 [patent_title] => 'ALTERED POLYPEPTIDES WITH INCREASED HALF-LIFE' [patent_app_type] => utility [patent_app_number] => 11/830537 [patent_app_country] => US [patent_app_date] => 2007-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 28940 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0166/20080166759.pdf [firstpage_image] =>[orig_patent_app_number] => 11830537 [rel_patent_id] =>[rel_patent_doc_number] =>)